PEG-IFNα

ApprovedBiologic

Gilead

PEG-IFNα is one of 161 biologic programs targeting Chronic Hepatitis. It is currently in Approved.

Indications

Total Trials

Active Trials

160

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic HepatitisActive, not recruiting

Chronic Hepatitis B Virus InfectionActive, not recruiting

FibrosisActive, not recruiting

Acute Myeloid LeukemiaActive, not recruiting

Hepatitis BActive, not recruiting

Chronic Hepatitis BRecruiting

Chronic HepatitisPhase 3

Active, not recruiting

Chronic Hepatitis B Virus InfectionPhase 2

Active, not recruiting

FibrosisApproved

Active, not recruiting

Acute Myeloid LeukemiaPhase 1/Phase 2

Active, not recruiting

Hepatitis BPhase 2

Active, not recruiting

Chronic Hepatitis BApproved

Recruiting

Competition

Competitive Landscape

804 competitors in Acute Myeloid Leukemia

#DrugCompanyPhaseTrials

Peony

Takeda

Phase 3

6 2

Empaveli

Gilead

Phase 3

4 3

Zarnestra

KKura Oncology, Inc.

Phase 3

9 4

Intron a

Sanofi

Phase 3

1 5

PEG-IFNα

Gilead

Approved

1 6

Diflucan

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

1 7

Salvage Chemotherapy

Daiichi Sankyo

Phase 3

1 8

Conventional Chemotherapy

SShanghai Jiao Tong University School of Medicine

Phase 3

1 9

Daunorubicin or Idarubicin

Novartis

Phase 3

1 10

Azacitadine

AbbVie

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Chronic Hepatitis B Virus Infection

NCT05771402

ApprovedRecruiting

Chronic Hepatitis B

NCT07573943

Q1 2027

Phase 2Recruiting

Chronic Hepatitis

NCT06425341

Q2 2027

Phase 2Active, not recruiting

Hepatitis B

NCT07069569

Phase 2Active, not recruiting

Chronic Hepatitis

NCT06491563

Q3 2027

Phase 2Recruiting

Chronic Hepatitis

NCT06650852

Clinical

Trials by Indication[1]

Chronic Hepatitis12 trials

A Study to Evaluate the Efficacy and Safety of Combination Therapy of BRII-179, BRII-835 and PEG-IFNα in Participants With Chronic Hepatitis B Virus (HBV) Infection (ENHANCE)

Recruiting·BBrii Biosciences Limited·Phase 2·NCT06650852·250 enrolled

The Study on Optimal Treatment and Clinical Outcome of Chronic Hepatitis B Patients With Inactive Hypoviremia

Unknown status·—··NCT05357235·1,200 enrolled

Study of Vaniprevir Plus PegIntron®/Ribavirin in Japanese Participants With Chronic Hepatitis C Who Relapsed After Treatment (MK-7009-044)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT01405937·51 enrolled

Show 9 more trials

Vaniprevir Administered With Pegylated-interferon and Ribavirin in Japanese Treatment-Naïve Chronic Hepatitis C Participants (MK-7009-043)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT01370642·294 enrolled

Efficacy & Safety of Tenofovir Disoproxil Fumarate (TDF) Plus Peginterferon α-2a (Peg-IFN) Versus TDF or Peg-IFN Monotherapy in Chronic Hepatitis B

Completed· Gilead logo

Gilead·Phase 4·NCT01277601·751 enrolled

The Study on Clinical Outcome and Treatment Optimization of Chronic Hepatitis B Patients With Hypoviremia

Unknown status·—··NCT05357183·1,200 enrolled

A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection

Completed·VVir Biotechnology, Inc.·Phase 1/2·NCT05612581·33 enrolled

A Multicenter, Randomized, Open, Parallel-designed Study to Evaluate the Efficacy and Safety of HRS-5635 Injection Alone or in Combination With Other Agents in Patients Treated for Chronic Hepatitis B

Recruiting·FFujian Shengdi Pharmaceutical Co., Ltd.·Phase 2·NCT06425341·369 enrolled

Vaniprevir Plus PegIntron®/Ribavirin in Japanese Participants With Chronic Hepatitis C Who Are Non-responders to Previous Treatment (MK-7009-045)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT01405560·42 enrolled

Exploring the Genome-wide Association Study of the Population With Clinical Cure Advantage in the Treatment of Chronic Hepatitis B With Long-acting Interferon

Recruiting·MMinghui Li··NCT06696664·120 enrolled

Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and PEG-IFNα Treating Chronic Hepatitis B Virus (HBV) Infection (ENRICH)

Active, not recruiting·BBrii Biosciences Limited·Phase 2·NCT06491563·150 enrolled

A Trial To Evaluate The Efficacy And Safety Of Multiple Combination Therapies In Participants With Chronic Hepatitis B

Completed· Roche logo

Roche·Phase 2·NCT04225715·281 enrolled

Chronic Hepatitis B Virus Infection3 trials

A Study Evaluating ABI-H0731-containing Regimens in Chinese Participants With Chronic Hepatitis B Virus Infection

Terminated·AAssembly Biosciences·Phase 2·NCT04781647·54 enrolled

A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained HBsAg Loss) (B)

Recruiting·TThe Second Affiliated Hospital of Chongqing Medical University·Phase 2·NCT05771402·120 enrolled

Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection

Active, not recruiting·VVir Biotechnology, Inc.·Phase 2·NCT04856085·244 enrolled

HCV Infection2 trials

SOF (Sovaldi®) +RBV for 16 or 24 Weeks and SOF+RBV+Peg-IFN for 12 Weeks in Adults With Genotype 2 or 3 Chronic HCV Infection

Completed· Gilead logo

Gilead·Phase 3·NCT01962441·601 enrolled

Open-Label Study of Sofusbuvir+Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies

Completed· Gilead logo

Gilead·Phase 3·NCT01625338·534 enrolled

Efficacy and Safety1 trial

Efficacy and Safety of Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection in Participants With Chronic Genotype 1, 2, 3, or 6 HCV Infection

Completed· Gilead logo

Gilead·Phase 2·NCT01826981·359 enrolled

Fibrosis1 trial

Optimized Treatment and Regression of HBV-induced Liver Fibrosis

Completed·—·Phase 4·NCT01938781·400 enrolled

5 more indications

Hepatitis B1 trial

A Multicenter Study of AHB-137 Injection Combined With Other Hepatitis B Drugs

Active, not recruiting·AAusper Biopharma Co., Ltd.·Phase 2·NCT07069569·127 enrolled

Acute Myeloid Leukemia1 trial

Peginterferon Alfa-2a to Enhance Anti-leukemic Responses After Allogeneic Transplantation in Acute Myeloid Leukemia

Completed·UUniversity of Michigan Rogel Cancer Center·Phase 1/2·NCT02328755·37 enrolled

Effectiveness1 trial

Comparative Effectiveness and Tolerability of Boceprevir vs Telaprevir

Completed·—·N/A·NCT02113631·50 enrolled

Combination Therapy1 trial

Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and PEG-IFNα Combination Therapy in Chronic HBV Patients

Active, not recruiting·BBrii Biosciences Limited·Phase 2·NCT05970289·86 enrolled

Chronic Hepatitis b1 trial

ASC22 Combined With Peg-IFNa in Achieving Functional Cure in Patients With Chronic Hepatitis B Virus Infection

Recruiting·TThe Second Affiliated Hospital of Chongqing Medical University·Approved·NCT07573943·150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 24 trial records for PEG-IFNα. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PEG-IFNα compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PEG-IFNα. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Gilead company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Approved[1]
Company: Gilead

PEG-IFNα

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q2 2027

Q3 2027

Trials by Indication[1]

Chronic Hepatitis12 trials

Chronic Hepatitis B Virus Infection3 trials

HCV Infection2 trials

Efficacy and Safety1 trial

Fibrosis1 trial

Hepatitis B1 trial

Acute Myeloid Leukemia1 trial

Effectiveness1 trial

Combination Therapy1 trial

Chronic Hepatitis b1 trial

References

Drug Info

Quick Facts

Related News